• Vesigard


  • Darifenacin Hydrobromide Extended-Release
  • Enablex
  • 7.5 mg, 15 mg
  • Cipla Ltd.

VESIGARD extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.


The recommended starting dose of VESIGARD extended-release tablets is 7.5 mg once daily. Based upon individual response, the dose may be increased to 15 mg once daily, as early as 2 weeks after starting therapy. VESIGARD extended-release tablets should be taken once daily along with any liquid. They may be taken with or without food, and should be swallowed whole and not chewed, divided or crushed.


VESIGARD extended-release tablets are contraindicated in patients with urinary retention, gastric retention or uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. VESIGARD extended-release tablets are also contraindicated in patients with known hypersensitivity to the drug or its ingredients.

VESIGARD ­7.5 extended-release tablets  ............... Strip pack of 10 tablets
VESIGARD­ 15 extended-release tablets   ............... Strip pack of 10 tablets